While these mutations activate the same upstream MEK/ERK pathway, studies in cancer cells have shown subtle but important differences in signaling activity between these mutation types, that may contribute to variable traits in AVM patients or affect pharmaceutical susceptibility [42,43]. This evidence concerns the gene MAP2K7 and cancer.